Etoricoxib is a selective cyclooxygenase-2 inhibitor, with a lower risk of gastrointestinal toxicity compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs). We evaluated the effectiveness and tolerability of etoricoxib in extremely elderly patients with chronic pain due to osteoarthritis (OA). A prospective, single-center, single-arm study was conducted, enrolling 19 extremely elderly men with OA (mean age 85.9, range 79-96 years), who responded inadequately to NSAIDs or other analgesics. Patients were switched to etoricoxib, 60 mg once daily for 4 weeks, without prior medication washout. Data were recorded before and after etoricoxib treatment. The primary endpoint was improvement in pain, assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) after the 4-week treatment. Other endpoints included the Brief Pain Inventory Short Form (BPI-SF), Treatment Satisfaction Questionnaire for Medication (TSQM), Short Form 36 (SF36), and European Quality of Life-5 Dimensions (EQ-5D). Safety and tolerability were assessed by collecting adverse events data. Pain and disability scores measured by WOMAC index were lower after treatment (pain, p ≤ 0.001; disability, p = 0.020). BPI-SF showed a significant improvement in joint function when walking and performing normal work (walking, p = 0.021; normal work, p = 0.030). SF36 scores improved for 7 out of 11 items after etoricoxib treatment (#1, p = 0.032; #4, p = 0.026; #5, p = 0.017; #6, p = 0.008; #7, p = 0.009; #8, p = 0.013; and #10, p = 0.038). EQ-5D showed a significant improvement in visual analogue scale scores (p = 0.036). TSQM results demonstrated a higher patient perception of overall satisfaction. No adverse events were reported. Pain relief, joint function, quality of life, and treatment satisfaction improved significantly in elderly patients with OA after etoricoxib administration.

中文翻译：

---

在极端的老年人中，依托考昔改善了骨关节炎的疼痛缓解，关节功能和生活质量。

Etoricoxib是一种选择性的环氧合酶2抑制剂，与传统的非甾体类抗炎药（NSAIDs）相比，具有较低的胃肠道毒性风险。我们评估了依托考昔在因骨关节炎（OA）引起的慢性疼痛的极老患者中的有效性和耐受性。进行了一项前瞻性，单中心，单臂研究，招募了19名OA老年男性（平均年龄85.9，范围79-96岁），他们对NSAID或其他镇痛药的反应不足。患者每天换一次60 mg的依托考昔，持续4周，而无需事先冲洗药物。依托昔布治疗前后记录数据。在治疗4周后，使用Western Ontario和McMaster University骨关节炎指数（WOMAC）评估了主要终点为疼痛改善。其他目标包括简短疼痛清单简短形式（BPI-SF），药物治疗满意度问卷（TSQM），简短形式36（SF36）和欧洲生活质量5维度（EQ-5D）。通过收集不良事件数据评估安全性和耐受性。治疗后通过WOMAC指数测量的疼痛和残疾评分较低（疼痛，p≤0.001；残疾，p = 0.020）。BPI-SF在行走和进行正常工作时显示出关节功能的显着改善（行走，p = 0.021；正常工作，p = 0.030）。依托昔布治疗后11项中有7项的SF36评分有所改善（＃1，p = 0.032;＃4，p = 0.026;＃5，p = 0.017;＃6，p = 0.008;＃7，p = 0.009;＃8 ，p = 0.013；和＃10，p = 0.038）。EQ-5D在视觉模拟量表评分上显示出显着改善（p = 0.036）。TSQM结果表明，患者对总体满意度的看法更高。没有不良反应的报道。服用依托昔布的老年OA患者的疼痛缓解，关节功能，生活质量和治疗满意度显着改善。